Health & Fitness
Fri, August 24, 2012
HENDERSON, Nev.--([ BUSINESS WIRE ])--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, marked its ten-year anniversary in business. The milestone is being celebrated by employees in the U.S. and a growing number of locations abroad as Spectrum expands its worldwide presence. Spectrum is headquartered in Henderson, Nevada, with its Research & Development facility located in Irvine, CA; additional locations include Spectrum Pharma Canada and the Companyas subsidiary, OncoRx, in Mumbai, India. Plans include establishing and expanding offices in Japan and in Europe to support international operations.
"Spectrum has dramatically transformed itself over the past decade from a start-up company with no approved products to a dynamic industry leader with two approved drugs, substantial R&D opportunities and a successful commercial infrastructure"
aSpectrum has dramatically transformed itself over the past decade from a start-up company with no approved products to a dynamic industry leader with two approved drugs, substantial R&D opportunities and a successful commercial infrastructure,a said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals who has led Spectrum from its inception. aOur mission and passion always have been to deliver better options for patients with cancer, and we are dedicated to building on our successes over the last decade as we look toward the future. Our commitment to our patients, our people and our investors helps explain why the company has continued to receive a number of merit awards, including One of the Best Companies to Work For in Orange County and One of the Fastest Growing Companies in North America. Further, our drugs have been featured in top medical conferences in the U.S. and abroad, as well as in multiple, major peer-reviewed publications. With a growing presence in the US, we are seeking to add more commercial products, build our pipeline with new products in development, expand our global presence, and continue to create a workplace that rewards excellence and is an exciting place to work. Based on these and other strong assets, we believe we are in a formidable position to continue the same growth pace over the next decade.a
More facts about Spectrumas 10th Anniversary:
- 10 years ago, the market cap was under $5 million; Spectrumas market cap reached $1 billion in July 2012.
- 2 Commercial drugs on the Market FUSILEV (levoleucovorin) for Injection in the U.S. and ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, with record sales of $122.4 million in the first half of 2012.
- The Companyas first full year of profitability was 2011.
- More than 50,000 cancer patients treated in the past 2-3 years.
- 10 pipeline drugs in the clinical development, with near-term catalysts including clinical data from late-stage trials.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum currently markets two oncology drugs a" FUSILEV (levoleucovorin) for Injection in the U.S. and ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at [ www.sppirx.com ].
Forward-looking statement a" This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC., ZEVALIN, and FUSILEV are registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CAREa" and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.